New ventures in life science: helping Arix's transformational M&A deal

15/01/2024

We're delighted to have helped Arix Bioscience plc with shareholder documentation for the all-share recommended acquisition by RTW Biotech Opportunities of its life sciences assets, followed by a reconstruction.

Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life science, while RTW Biotech Opportunities is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors.

The transaction effectively delivers a scaled pro-forma RTW Bio with an expected pro-forma NAV of approximately $550 million, an increase of 63 per cent.

Thanks to our wonderful clients at Clifford Chance and Arix Bioscience for the opportunity to work on this transformational deal, and we wish the company every success at the next stage of its incredible journey.

To find out more about how we can ensure the success of your most critical M&A deals, chat with us today: hello@blackandcallow.com.

Back to News